Next Article in Journal
Metabolomics of Two Pecan Varieties Provides Insights into Scab Resistance
Previous Article in Journal
Lung Protection Strategies during Cardiopulmonary Bypass Affect the Composition of Bronchoalveolar Fluid and Lung Tissue in Cardiac Surgery Patients
Article

Metabolomics Approach for Validation of Self-Reported Ibuprofen and Acetaminophen Use

1
Nutrition and Health Sciences, Laney Graduate School, Emory University 615 Michael Street, Atlanta, GA 30322, USA
2
Behavioral and Epidemiology Research Group, American Cancer Society, 250 Williams Street, NW, Atlanta, GA 30303, USA
*
Author to whom correspondence should be addressed.
Disclaimer: The views expressed here are those of the authors and do not necessarily represent the American Cancer Society or the American Cancer Society—Cancer Action Network.
Metabolites 2018, 8(4), 55; https://doi.org/10.3390/metabo8040055
Received: 29 August 2018 / Revised: 18 September 2018 / Accepted: 19 September 2018 / Published: 21 September 2018
Over-the-counter analgesic use is common and is typically assessed through self-report; therefore, it is subject to misclassification. Detection of drug metabolites in biofluids offers a viable tool for validating self-reported analgesic use. Thus, the aim of this study was to determine the utility of a metabolomics approach for the validation of acetaminophen and ibuprofen use in blood samples. Untargeted mass spectrometry-based metabolomics analysis was conducted in serum samples from 1547 women and plasma samples from 556 men. The presence of two metabolites each for acetaminophen and ibuprofen at levels at or above a defined cutoff value was used to determine concordance with self-reported use. For acetaminophen use based on the presence of both acetaminophen and acetamidophenylglucuronide, concordance was 98.5–100% among individuals reporting use today, and 79.8–91.4% for those reporting never or rare use. Ibuprofen use based on the presence of both carboxyibuprofen and hydroxyibuprofen resulted in concordance of 51.3–52.5% for individuals reporting use today and 99.4–100% for those reporting never or rare use. Our findings suggest that an untargeted metabolomics approach in blood samples may be useful for validating self-reported acetaminophen use. However, this approach appears unlikely to be suitable for validating ibuprofen use. View Full-Text
Keywords: metabolomics; acetaminophen; ibuprofen; analgesics; molecular epidemiology metabolomics; acetaminophen; ibuprofen; analgesics; molecular epidemiology
Show Figures

Figure 1

MDPI and ACS Style

Dennis, K.K.; Carter, B.D.; Gapstur, S.M.; Stevens, V.L. Metabolomics Approach for Validation of Self-Reported Ibuprofen and Acetaminophen Use. Metabolites 2018, 8, 55. https://doi.org/10.3390/metabo8040055

AMA Style

Dennis KK, Carter BD, Gapstur SM, Stevens VL. Metabolomics Approach for Validation of Self-Reported Ibuprofen and Acetaminophen Use. Metabolites. 2018; 8(4):55. https://doi.org/10.3390/metabo8040055

Chicago/Turabian Style

Dennis, Kristine K., Brian D. Carter, Susan M. Gapstur, and Victoria L. Stevens 2018. "Metabolomics Approach for Validation of Self-Reported Ibuprofen and Acetaminophen Use" Metabolites 8, no. 4: 55. https://doi.org/10.3390/metabo8040055

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop